Exact Sciences released data from a study of its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for colorectal cancer and 31.2% for advanced precancerous lesions.

A snowman picking his nose made people who typically avoid informataion about colorectal cancer more likely to take a quiz regarding their personal risk ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Over the weekend, during the leadup to Exact Sciences announcing data from a blood-based colon cancer test, Guardant Health co-CEO AmirAli Talasaz challenged Exact’s CEO, Kevin Conroy ...

Totò Schillaci, who passed away today, September 18, had been suffering from colon cancer for some time. His condition had ...

The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

Totò Schillaci, who passed away today, September 18, had been suffering from colon cancer for some time. His condition had ...

Blood in your bowels could be a sign of several potentially serious health conditions, and understanding the cause is crucial ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

While the new Shield blood test may motivate more people to get screened for colorectal cancer, it also comes with downsides, ...